191 related articles for article (PubMed ID: 32467666)
1.
Keenan B; Finol-Urdaneta RK; Hope A; Bremner JB; Kavallaris M; Lucena-Agell D; Oliva MÁ; Díaz JF; Vine KL
Cancer Cell Int; 2020; 20():170. PubMed ID: 32467666
[TBL] [Abstract][Full Text] [Related]
2. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
3. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions.
Liaw TY; Salam NK; McKay MJ; Cunningham AM; Hibbs DE; Kavallaris M
Mol Cancer Ther; 2008 Oct; 7(10):3150-9. PubMed ID: 18852118
[TBL] [Abstract][Full Text] [Related]
4. N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell lines.
Vine KL; Belfiore L; Jones L; Locke JM; Wade S; Minaei E; Ranson M
Heliyon; 2016 Jan; 2(1):e00060. PubMed ID: 27441242
[TBL] [Abstract][Full Text] [Related]
5. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
6. Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line.
Geyp M; Ireland CM; Pittman SM
Leukemia; 1996 Mar; 10(3):447-55. PubMed ID: 8642860
[TBL] [Abstract][Full Text] [Related]
7. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
10. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
11. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
Avramis IA; Kwock R; Avramis VI
Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283
[TBL] [Abstract][Full Text] [Related]
12. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations.
Verrills NM; Walsh BJ; Cobon GS; Hains PG; Kavallaris M
J Biol Chem; 2003 Nov; 278(46):45082-93. PubMed ID: 12949081
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
15. Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells.
Lemoli RM; Igarashi T; Knizewski M; Acaba L; Richter A; Jain A; Mitchell D; Levy J; Gulati SC
Blood; 1993 Feb; 81(3):793-800. PubMed ID: 8427970
[TBL] [Abstract][Full Text] [Related]
16. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
Chiang CD; Song EJ; Yang VC; Chao CC
Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Ooko E; Alsalim T; Saeed B; Saeed MEM; Kadioglu O; Abbo HS; Titinchi SJJ; Efferth T
Toxicol Appl Pharmacol; 2016 Aug; 305():216-233. PubMed ID: 27318188
[TBL] [Abstract][Full Text] [Related]
19. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A; Inukai T; Kagami K; Abe M; Takagi M; Fukushima T; Fukushima H; Nanmoku T; Terui K; Ito T; Toki T; Ito E; Fujimura J; Goto H; Endo M; Look T; Kamps M; Minegishi M; Takita J; Inaba T; Takahashi H; Ohara A; Harama D; Shinohara T; Somazu S; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2019 Sep; 8(11):5274-5288. PubMed ID: 31305009
[TBL] [Abstract][Full Text] [Related]
20. Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells.
Geyp M; Ireland CM; Pittman SM
Cancer Genet Cytogenet; 1996 Apr; 87(2):116-22. PubMed ID: 8625256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
